Your browser doesn't support javascript.
loading
Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment.
Wang, Yufeng; Drum, David L; Sun, Ruochuan; Zhang, Yida; Chen, Feng; Sun, Fengfei; Dal, Emre; Yu, Ling; Jia, Jingyu; Arya, Shahrzad; Jia, Lin; Fan, Song; Isakoff, Steven J; Kehlmann, Allison M; Dotti, Gianpietro; Liu, Fubao; Zheng, Hui; Ferrone, Cristina R; Taghian, Alphonse G; DeLeo, Albert B; Ventin, Marco; Cattaneo, Giulia; Li, Yongxiang; Jounaidi, Youssef; Huang, Peigen; Maccalli, Cristina; Zhang, Hanyu; Wang, Cheng; Yang, Jibing; Boland, Genevieve M; Sadreyev, Ruslan I; Wong, LaiPing; Ferrone, Soldano; Wang, Xinhui.
Afiliação
  • Wang Y; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Drum DL; Department of General Surgery, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Sun R; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Zhang Y; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Chen F; Department of Gastrointestinal Surgery and General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Sun F; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Dal E; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Yu L; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Jia J; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Arya S; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Jia L; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Fan S; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Isakoff SJ; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Kehlmann AM; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Dotti G; Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
  • Liu F; Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
  • Zheng H; Lineberger Comprehensive Cancer Center and Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA.
  • Ferrone CR; Department of Hepatobiliary & Pancreatic Surgery and Liver Transplantation, Anhui Medical University, Hefei, Anhui, China.
  • Taghian AG; Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • DeLeo AB; Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Ventin M; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Cattaneo G; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Li Y; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Jounaidi Y; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Huang P; Department of Gastrointestinal Surgery and General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Maccalli C; Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Zhang H; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Wang C; Research Department, Sidra Medicine, Doha, Qatar.
  • Yang J; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Boland GM; Vincent Center for Reproductive Biology, Vincent Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Sadreyev RI; Center for Comparative Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Wong L; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Ferrone S; Department of Molecular Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Wang X; Department of Molecular Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Nat Commun ; 14(1): 5727, 2023 09 15.
Article em En | MEDLINE | ID: mdl-37714830
ABSTRACT
The poor efficacy of chimeric antigen receptor T-cell therapy (CAR T) for solid tumors is due to insufficient CAR T cell tumor infiltration, in vivo expansion, persistence, and effector function, as well as exhaustion, intrinsic target antigen heterogeneity or antigen loss of target cancer cells, and immunosuppressive tumor microenvironment (TME). Here we describe a broadly applicable nongenetic approach that simultaneously addresses the multiple challenges of CAR T as a therapy for solid tumors. The approach reprograms CAR T cells by exposing them to stressed target cancer cells which have been exposed to the cell stress inducer disulfiram (DSF) and copper (Cu)(DSF/Cu) plus ionizing irradiation (IR). The reprogrammed CAR T cells acquire early memory-like characteristics, potent cytotoxicity, enhanced in vivo expansion, persistence, and decreased exhaustion. Tumors stressed by DSF/Cu and IR also reprogram and reverse the immunosuppressive TME in humanized mice. The reprogrammed CAR T cells, derived from peripheral blood mononuclear cells of healthy donors or metastatic female breast cancer patients, induce robust, sustained memory and curative anti-solid tumor responses in multiple xenograft mouse models, establishing proof of concept for empowering CAR T by stressing tumor as a promising therapy for solid tumors.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptores de Antígenos Quiméricos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptores de Antígenos Quiméricos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article